BNC105 Data Presented at Lorne Cancer Conference
Bionomics Limited (ASX:BNO; ADR:BMICY) today announced that BNC105 would be the subject of three poster presentations at the 23rd Lorne Cancer Conference, Victoria Australia.
Thursday 10 February 2011:
"Functional and molecular biomarker analysis demonstrates pharmacological activity for the novel vascular disrupting agent BNC105 in a first in human clinical study", to be presented by Dr David Bibby, Bionomics' Director Drug Development.
"Discovery and clinical development of BNC105, a tubulin targeting small molecule that selectively disrupts the vasculature in solid tumours", to be presented by Dr Gabriel Kremmidiotis, Bionomics' Vice President Research and Development.
Friday 11 February 2011:
"Evaluation of the anti-cancer effects of the tumour selective Vascular Disruptive Agent BNC105 in preclinical renal cancer models", to be presented by Dr Tina Lavranos, Head of Oncology Services, Neurofit.
The posters can be found on the Bionomics website www.bionomics.com.au.
Download this document